The report highlights the company's commitment to sustainable growth through glycoscience research and development, with a focus on new drug and medical device creation. Key highlights include the launch of HERNICORE®, a treatment for lumbar disc herniation, in Japan, the ongoing development of SI-613, a new osteoarthritis treatment agent, and the company's expansion into the knee osteoarthritis market with Gel-One® and other products. The report also emphasizes the company's commitment to social responsibility, including its support of the Mizutani Foundation for Glycoscience and its ongoing research assistance and sponsorship activities related to glycoscience.
Issuing Company Seikagaku Corporation
Report Type Integrated Report
Report Language EN
Report Filesize 2.19 MB
No. of Pages 22 pages
Reporting periodApril 1, 2017-March 31, 2018
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards Unknown
Materiality Assessmentfalse